Payment overview · 2025
General Payments
$12,921.47
78 reported records · 22 companies
Healthcare provider profile · identity verified
Stephen Lanier Nelson, MD
Allopathic & Osteopathic Physicians|Family Medicine · MEDFORD, OR · NPI 1356362008
Verified facts
What the public records show
CMS Open Payments records show Stephen Lanier Nelson, MD received $12,921.47 in general payments during 2025 across 78 reported records.
CSL Plasma Inc. accounted for 89.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Plasma Inc. | Unresolved — no canonical attribution shown | $11,500.00 | 89.0% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $260.46 | 2.0% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $219.20 | 1.7% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $120.58 | 0.9% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $95.47 | 0.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.31 | 0.7% | 5 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $76.64 | 0.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $71.08 | 0.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.92 | 0.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.57 | 0.5% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $57.02 | 0.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.66 | 0.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.27 | 0.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.81 | 0.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.49 | 0.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.20 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.15 | 0.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.61 | 0.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.96 | 0.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.75 | 0.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $20.61 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.71 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $11,500.00 | 16 |
| Food and Beverage | $1,405.48 | 61 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.32 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $120.58 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.77 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.99 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.99 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $108.21 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $95.47 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.03 | 4 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $76.64 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $71.08 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $57.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.05 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.71 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.48 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 82 |
| Lisinopril | Lisinopril | 302 | 75 |
| Omeprazole | Omeprazole | 243 | 57 |
| Gabapentin | Gabapentin | 213 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 47 |
| Trazodone Hcl | Trazodone Hcl | 139 | 31 |
| Metformin Hcl Er | Metformin Hcl | 138 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 36 |
| Furosemide | Furosemide | 133 | 34 |
| Potassium Chloride | Potassium Chloride | 117 | 32 |
| Losartan Potassium | Losartan Potassium | 111 | 33 |
| Allopurinol | Allopurinol | 103 | 23 |
| Eliquis | Apixaban | 97 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 20 |
| Metformin Hcl | Metformin Hcl | 88 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 18 |
| Famotidine | Famotidine | 82 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 23 |
| Estradiol | Estradiol | 81 | 14 |
| Prednisone | Prednisone | 81 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 17 |
| Donepezil Hcl | Donepezil Hcl | 72 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 24 |
| Bupropion Xl | Bupropion Hcl | 67 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 15 |
| Montelukast Sodium | Montelukast Sodium | 65 | 14 |
| Simvastatin | Simvastatin | 63 | 16 |
| Carvedilol | Carvedilol | 59 | 11 |
| Fluconazole | Fluconazole | 57 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 29 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Sertraline Hcl | Sertraline Hcl | 48 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Ozempic | Semaglutide | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 24 |
| Farxiga | Dapagliflozin Propanediol | 43 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 12 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | 12 |
| Diltiazem 12hr Er | Diltiazem Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Linzess | Linaclotide | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,921.47 · 78 records | CSL Plasma Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, EVENITY, FARXIGA, GEMTESA, GVOKE HYPOPEN, INSPIRE, KISUNLA, Kerendia, Korlym, MOUNJARO, NEXPLANON, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, REZDIFFRA, Restrata Wound Matrix, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, WATCHMAN Access System, XIFAXAN, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error